Literature DB >> 27699044

Partial response to chemotherapy in a patient with retroperitoneal inflammatory myofibroblastic tumor.

Ming Chen1, Lihua Zhang2, Guochun Cao3, Weidong Zhu1, Xuqiu Chen1, Quan Fang1.   

Abstract

Retroperitoneal inflammatory myofibroblastic tumor (IMT) is a rare lesion of unknown etiology. The management of IMT may be challenging due to its intermediate malignant potential, the possibility of local recurrence after surgical resection and its unique anatomic location, which makes radical resection impossible due to its proximity to vital structures. Thus, treatment for recurrence and metastasis mainly relies on chemotherapy. We herein report a case of a 60-year-old man with an IMT sized 6.7×5.1 cm, located in the left adrenal area, which was identified by a computed tomography (CT) scan of the abdomen. Radical surgical resection of the tumor was not feasible, as it was fixed to the left renal artery. After 5 months, the patient underwent CT-guided radiofrequency ablation of the re-growing tumor. An unresectable mass was detected in the patient's rectum by a CT scan of the pelvis. Subsequently, the patient underwent chemotherapy for the recurring and metastatic tumors. The chemotherapeutic regimens included epirubicin, dacarbazine and docetaxel. Over the last 6 months, after three cycles of therapy, the sizes of the primary and metastatic tumors had decreased on the follow-up CT scan. Thus, chemotherapy effectively controlled the disease in this case, following unsuccessful surgical resection and radiofrequency ablation. The present case report highlights the complexity of treatment in such cases and the significance of designing a clinical protocol for the treatment of IMT.

Entities:  

Keywords:  chemotherapy; inflammatory myofibroblastic tumor; retroperitoneum

Year:  2016        PMID: 27699044      PMCID: PMC5038221          DOI: 10.3892/mco.2016.967

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  16 in total

1.  Regression of nonresectable inflammatory myofibroblastic tumours after treatment with nonsteroidal anti-inflammatory drugs.

Authors:  R Przkora; U Bolder; S Schwarz; K W Jauch; J Spes; R Andreesen; A Mackensen
Journal:  Eur J Clin Invest       Date:  2004-04       Impact factor: 4.686

2.  Inflammatory myofibroblastic tumour.

Authors:  Ozgur Firat; Safak Ozturk; Taner Akalin; Ahmet Coker
Journal:  Can J Surg       Date:  2009-06       Impact factor: 2.089

3.  Retroperitoneal myofibroblastic inflammatory tumor.

Authors:  Sonia Ziadi; Mounir Trimeche; Sarra Mestiri; Nadia Boujelbene; Moncef Mokni; Badreddine Sriha; Sadok Korbi
Journal:  Tunis Med       Date:  2011-04

Review 4.  Inflammatory myofibroblastic tumor, inflammatory fibrosarcoma, and related lesions: an historical review with differential diagnostic considerations.

Authors:  C M Coffin; L P Dehner; J M Meis-Kindblom
Journal:  Semin Diagn Pathol       Date:  1998-05       Impact factor: 3.464

5.  Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors.

Authors:  C A Griffin; A L Hawkins; C Dvorak; C Henkle; T Ellingham; E J Perlman
Journal:  Cancer Res       Date:  1999-06-15       Impact factor: 12.701

6.  Inflammatory myofibroblastic tumor (IMT) of the pancreas.

Authors:  Hiroshi Yamamoto; Kazuo Watanabe; Matsuo Nagata; Kentaro Tasaki; Ichiro Honda; Satoshi Watanabe; Hiroaki Soda; Toshinao Takenouti
Journal:  J Hepatobiliary Pancreat Surg       Date:  2002

7.  Inflammatory myofibroblastic tumor successfully treated with chemotherapy and nonsteroidals: a case report.

Authors:  Yun-Lu Tao; Zhen-Jun Wang; Jia-Gang Han; Ping Wei
Journal:  World J Gastroenterol       Date:  2012-12-21       Impact factor: 5.742

8.  Successful preoperative treatment of pediatric bladder inflammatory myofibroblastic tumor with anti-inflammatory therapy.

Authors:  Alisa Berger; Christina Kim; Nathan Hagstrom; Fernando Ferrer
Journal:  Urology       Date:  2007-08       Impact factor: 2.649

Review 9.  Inflammatory myofibroblastic tumor presenting as a pancreatic mass: a case report and review of the literature.

Authors:  Surakit Pungpapong; Xochi J Geiger; Massimo Raimondo
Journal:  JOP       Date:  2004-09-10

10.  Inflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases.

Authors:  Cheryl M Coffin; Jason L Hornick; Christopher D M Fletcher
Journal:  Am J Surg Pathol       Date:  2007-04       Impact factor: 6.394

View more
  7 in total

1.  Inflammatory myofibroblastic tumor of the spermatic cord: two cases and review of the literature.

Authors:  Huseyin Aydemir; Salih Budak; Zeynep Kahyaoglu; Sukru Kumsar
Journal:  Ann Saudi Med       Date:  2020-02-06       Impact factor: 1.526

2.  Retroperitoneal inflammatory myofibroblastic tumor: A case report.

Authors:  Oliveira Carlos; Costa Rui; Estêvão Amélia; Caseiro-Alves Filipe
Journal:  Eur J Radiol Open       Date:  2017-02-27

3.  Anaplastic lymphoma kinase-negative pulmonary inflammatory myofibroblastic tumor with multiple metastases and its treatment by Apatinib: A case report.

Authors:  Qiuxia Liu; Jianguo Wei; Xizhong Liu; Jianfang Wang
Journal:  Medicine (Baltimore)       Date:  2019-12       Impact factor: 1.817

4.  Inflammatory myofibroblastic tumor of the spermatic cord: two cases and review of the literature.

Authors:  Huseyin Aydemir; Salih Budak; Zeynep Kahyaoglu; Sukru Kumsar
Journal:  Ann Saudi Med       Date:  2020-02-06       Impact factor: 1.526

5.  Robot assisted laparoscopic partial cystectomy for inflammatory myofibroblastic tumor with simultaneous intraoperative flexible cystoscopy for tumor mapping.

Authors:  Shane F Batie; Caitlin T Coco; Niccolo M Passoni; Angelena B Edwards; Bruce J Schlomer; Craig A Peters
Journal:  Urol Case Rep       Date:  2022-03-28

6.  A huge recurrent retroperitoneal inflammatory myofibroblastic tumor implicating renal and ureter: a case report.

Authors:  Tianle Zhu; Pan Gao; Jingjing Gao; Xi Liu; Xiansheng Zhang
Journal:  Transl Cancer Res       Date:  2021-10       Impact factor: 1.241

7.  Outstanding Response in a Patient With ROS1-Rearranged Inflammatory Myofibroblastic Tumor of Soft Tissues Treated With Crizotinib: Case Report.

Authors:  Danila Comandini; Fabio Catalano; Massimiliano Grassi; Guido Pesola; Rossella Bertulli; Antonio Guadagno; Bruno Spina; Matteo Mascherini; Franco De Cian; Federico Pistoia; Sara Elena Rebuzzi
Journal:  Front Oncol       Date:  2021-06-15       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.